Potential Therapeutic Effects of the Neural Stem Cell-Targeting Antibody Nilo1 in Patient-Derived Glioblastoma Stem Cells.
Nilo1
antibody
glioblastoma
glioma stem cells
immunotherapy
neural stem cells
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
03
2020
accepted:
28
07
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most devastating and least treatable brain tumor with median survival <15 months and extremely high recurrence rates. Promising results of immune checkpoint blockade obtained from pre-clinical studies in mice did not translate to clinic, and new strategies are urgently needed, particularly those targeting GBM stem cells (GSCs) that are held responsible for drug resistance and tumor recurrence. Patient-derived GSC cultures are critical for finding effective brain tumor therapies. Here, we investigated the ability of the recently described monoclonal antibody Nilo1 to specifically recognize GSCs isolated from GBM surgical samples. We employed five patient-derived GSC cultures with different stemness marker expression and differentiation potential, able to recapitulate original tumors when xenotransplanted
Identifiants
pubmed: 32974206
doi: 10.3389/fonc.2020.01665
pmc: PMC7468525
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1665Informations de copyright
Copyright © 2020 Rackov, Iegiani, Uribe, Quezada, Belda-Iniesta, Escobedo-Lucea, Silva, Puig, González-Rumayor and Ayuso-Sacido.
Références
Mol Neurobiol. 2014 Feb;49(1):187-98
pubmed: 23881416
Cell. 1990 Feb 23;60(4):585-95
pubmed: 1689217
Cancer Cell. 2012 Jul 10;22(1):21-35
pubmed: 22789536
Stem Cells Dev. 2006 Jun;15(3):423-35
pubmed: 16846378
Cell. 1993 Aug 27;74(4):609-19
pubmed: 8358790
Cancer Med. 2018 May;7(5):2064-2077
pubmed: 29577645
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Cell Cycle. 2010 May 15;9(10):1893-900
pubmed: 20436288
Stem Cells. 2009 Dec;27(12):2928-40
pubmed: 19725119
Neuroscience. 2010 Sep 1;169(3):1473-85
pubmed: 20580784
Front Oncol. 2019 Aug 20;9:779
pubmed: 31482066
J Cell Biol. 1995 Oct;131(1):227-34
pubmed: 7559779
Neurosurgery. 2008 Jan;62(1):223-9; discussion 229-31
pubmed: 18300911
Brain Res. 2003 Dec 12;993(1-2):18-29
pubmed: 14642827
Front Immunol. 2017 Nov 09;8:1509
pubmed: 29170667
Cell Cycle. 2016;15(2):196-212
pubmed: 26825227
Leuk Res. 2004 Oct;28(10):1089-96
pubmed: 15289023
Cancer Cell. 2009 Jan 6;15(1):45-56
pubmed: 19111880
Oncotarget. 2017 Oct 6;8(53):91779-91794
pubmed: 29207684
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Glia. 2020 Jun;68(6):1228-1240
pubmed: 31868967
Oncotarget. 2017 Jan 3;8(1):1416-1428
pubmed: 27902458
Blood. 1997 Dec 15;90(12):5013-21
pubmed: 9389721
Cell Stem Cell. 2009 Jun 5;4(6):568-80
pubmed: 19497285
Oncogene. 2004 Dec 16;23(58):9392-400
pubmed: 15558011
Cancer Res. 2007 May 1;67(9):4010-5
pubmed: 17483311
PLoS One. 2013 Jul 09;8(7):e67870
pubmed: 23874459
Neural Regen Res. 2015 Oct;10(10):1574-5
pubmed: 26692845
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Stem Cell Res. 2015 Jan;14(1):114-29
pubmed: 25564310
Oncotarget. 2016 Oct 4;7(40):65888-65901
pubmed: 27589567
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119
Acta Neuropathol. 1987;74(2):105-23
pubmed: 3314309
Br J Cancer. 2008 Jul 8;99(1):100-9
pubmed: 18542072
Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
pubmed: 28675164
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318